Status:
COMPLETED
S100B in Intensive Care Patients With and Without Traumatic Brain Injury
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Conditions:
Tumor
Brain Injuries
Eligibility:
All Genders
18+ years
Brief Summary
The neurotrophic protein S100B has been promoted as a neuromarker for decades, and to reflect the severity of brain injury. On the other hand, S100B is a tumor marker. The interpretation of its serum ...
Detailed Description
Patients of the Department of Neurosurgery, University of Erlangen-Nuremberg, undergoing surgery for sellar lesions were prospectively included. The study protocol was approved by the local Ethical Co...
Eligibility Criteria
Inclusion
- patients of the Department of Neurosurgery, University of Erlangen Nürnberg, patients with traumatic brain injury,
- patients with intracranial tumor,
- intensive care patients,
- informed written consent was given by the Patient or the next of kin in each case.
Exclusion
- age under 18
- pregnancy
Key Trial Info
Start Date :
July 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2019
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04501315
Start Date
July 1 2007
End Date
June 30 2019
Last Update
August 6 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.